Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel Bin Ng"'
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The relationships between developmental strategies for additional indications and drug price revisions have not been thoroughly studied. Here, we investigated the price revisions for anticancer drugs approved in Japan. Methods The
Externí odkaz:
https://doaj.org/article/883442c9c82b491d81dc865bc793331c
Autor:
Hideki Maeda, Daniel Bin Ng
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Recently, there has been a growing trend in clinical development to utilize real-world data (RWD) to improve the efficiency of drug/medical device development. Especially, the use of RWD to generate real-world evidence (RWE) in regulatory approval is
Externí odkaz:
https://doaj.org/article/0a22d32c7af64806aac6a5385712b91e
Publikováno v:
PharmacoEconomics Open
Objectives The aim of this study was to evaluate the cost effectiveness of mirabegron relative to two antimuscarinics, oxybutynin extended release (ER) and tolterodine ER, in patients with overactive bladder (OAB) from the perspective of a third-part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb1c7da41c288932a0ea177ddac36cd
https://doi.org/10.1007/s41669-019-0149-9
https://doi.org/10.1007/s41669-019-0149-9
Publikováno v:
Journal of Medical Economics. 20:1272-1280
To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the US who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron.A retrospective observational claims analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d08ff5e0555c886760fa07660eded75
https://doi.org/10.1080/13696998.2017.1367300
https://doi.org/10.1080/13696998.2017.1367300